innerbuddies gut microbiome testing

Gut Microbiome in Cirrhosis and Hepatic Encephalopathy: Evidence & Key Findings

In cirrhosis, the gut–liver axis becomes dysregulated: reduced bile flow, altered intestinal motility, and immune changes allow more gut microbes and microbial products to “reach” the liver and systemic circulation. This shift in the gut microbiome is closely linked with the development and worsening of complications—particularly hepatic encephalopathy (HE), a neurocognitive syndrome driven in part by gut-derived metabolites and toxin burden.

A key theme across the evidence is intestinal dysbiosis and increased intestinal permeability (“leaky gut”), which can raise exposure to ammonia and other neuroactive compounds. Microbial metabolism influences ammonia generation and detoxification pathways—while bacterial products such as endotoxin (LPS) can promote systemic and hepatic inflammation. In HE, inflammation and altered microbial signaling may further impair ammonia handling and neurotransmission, helping explain why symptoms can fluctuate with gut changes.

What today’s research emphasizes is that the microbiome is not only a marker of disease but also a modifiable driver. Changes in microbial communities can affect short-chain fatty acids, bile acid transformations, gut barrier integrity, and toxin-producing pathways—each relevant to cirrhosis progression and HE risk. Emerging microbiome-targeted strategies (e.g., modulation of gut ecology through antibiotics, probiotics/prebiotics, and therapies designed to reduce toxic metabolite production) aim to restore a healthier gut–liver balance and reduce HE episodes, aligning mechanism with clinical outcomes.

Order Gut Microbiome Test for Cirrhosis & Hepatic Encephalopathy Insights Order Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Cirrhosis / hepatic encephalopathy context

Cirrhosis reshapes the gut-liver axis through dysbiosis, increased intestinal permeability, and portal hypertension, enabling translocation of endotoxin/LPS and other microbial products into the portal circulation. This drives systemic inflammation and worsens liver injury, while also perturbing bile-acid metabolism and nitrogen handling via disrupted microbial functions.

Hepatic encephalopathy (HE) is a neuropsychiatric complication linked to these microbiome-driven processes. Altered ammonia production and impaired clearance, along with inflammatory mediators and altered neuroactive metabolism, contribute to sleep disturbances, confusion, and, in severe cases, coma. Dysbiosis shifts fermentation pathways and reduces barrier integrity, promoting neuroinflammation and brain edema.

Clinically, HE prevalence is substantial in cirrhosis (roughly 30–40% lifetime, higher in decompensated disease) with notable recurrence after overt episodes. Microbiome testing and targeted gut-directed therapies (rifaximin, lactulose, probiotics/prebiotics) aim to reduce toxin production, improve barrier function, and personalize care. The article also highlights InnerBuddies as a tool to profile gut ecosystems, guide management, and monitor shifts toward less inflammatory, more barrier-supportive microbiomes.

  • Loss of butyrate-producing, barrier-supporting taxa (e.g., Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale, Lachnospiraceae XIVa) reduces gut barrier integrity and elevates HE risk.
  • Expansion of pro-inflammatory/pathogenic taxa (Enterococcus spp., Streptococcus spp., Enterobacteriaceae such as Escherichia/Shigella) and Veillonella/Ruminococcus gnavus is linked to endotoxemia and systemic inflammation in cirrhosis.
  • Akkermansia muciniphila depletion weakens the mucus layer and gut barrier, facilitating toxin translocation.
  • Depletion of beneficial taxa such as Bifidobacterium spp. and Lactobacillus spp. lowers colonization resistance and SCFA production, worsening dysbiosis.
  • Microbial urease and polyamine/nitrogen metabolism pathways increase ammonia generation, contributing to hepatic encephalopathy.
  • Dysbiosis-driven bile-acid signaling alterations (FXR/TGR5) impair gut barrier function and promote inflammatory signaling.
  • Increased translocation of endotoxin/LPS from gut to portal circulation fuels systemic inflammation and liver injury.
Order Gut Microbiome Test for Cirrhosis & Hepatic Encephalopathy Insights Order Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Other liver-related topics

Cirrhosis is the end-stage consequence of chronic liver injury and is characterized by impaired hepatic detoxification, altered bile flow, and progressive portal hypertension. These changes reshape the gut environment—often causing dysbiosis (a shift in microbial composition), increased intestinal permeability (“leaky gut”), and reduced beneficial microbial functions. In this setting, gut-derived metabolites and bacterial products (e.g., endotoxin/LPS and other microbial toxins) can more easily translocate across the intestinal barrier and enter the portal circulation, where the failing liver cannot clear them effectively. The result is a cycle of inflammation, metabolic dysfunction, and worsening liver injury.

Hepatic encephalopathy (HE) is a neuropsychiatric complication of advanced liver disease and is strongly linked to microbiome-driven pathways. The gut microbiota can influence ammonia generation and utilization, as well as the production of other neuroactive compounds. When ammonia and inflammatory mediators rise, they contribute to altered neurotransmission and cerebral edema—clinically presenting as confusion, sleep disturbances, impaired attention, and in severe cases coma. Dysbiosis and intestinal permeability appear to promote HE by increasing the load of nitrogenous substrates and microbial products reaching the gut–liver–brain axis, while also disrupting normal microbial metabolism that would otherwise help maintain gut barrier integrity and limit toxin production.

Current evidence supports the concept of a gut–liver–brain continuum in cirrhosis and HE, with growing interest in how specific microbial taxa and functional pathways correlate with HE risk and outcomes. Research highlights roles for endotoxemia, inflammatory signaling, and ammonia-related mechanisms, alongside bile-acid and short-chain fatty acid (SCFA) changes that may affect gut barrier function and host metabolism. Emerging microbiome-targeted strategies—such as non-absorbable antibiotics (e.g., rifaximin in HE management), lactulose-based approaches that modify gut conditions, and investigational interventions like probiotics/synbiotics, prebiotics, and fecal microbiota–related therapies—aim to reduce gut-derived toxins, modulate inflammation, and improve microbial function, though patient selection and long-term efficacy remain active areas of study.

  • Confusion, disorientation, or altered mental status
  • Day-night sleep reversal (insomnia with daytime somnolence)
  • Asterixis (flapping tremor)
  • Excessive sleepiness or fatigue
  • Mood or behavior changes (irritability, anxiety, agitation)
  • Bradykinesia or difficulty with concentration/attention
  • Constipation or diarrhea (bowel habit changes)
Order Gut Microbiome Test for Cirrhosis & Hepatic Encephalopathy Insights Order Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Cirrhosis / hepatic encephalopathy context

This content is relevant for people living with cirrhosis—especially advanced disease where portal hypertension and impaired liver detoxification allow gut-derived toxins to enter the bloodstream—and for clinicians caring for them. It is also aimed at patients and caregivers who want to understand how changes in gut microbiota (dysbiosis) and intestinal barrier function (“leaky gut”) can contribute to ongoing liver inflammation and worsening hepatic dysfunction.

It’s particularly relevant for those experiencing hepatic encephalopathy (HE) symptoms, such as confusion or altered mental status, sleep–wake cycle disruption (day-night reversal), and asterixis (flapping tremor). The focus is useful when HE presents with mood or behavior changes (irritability, anxiety, agitation), excessive sleepiness or fatigue, and problems with attention or concentration, because these can reflect gut–liver–brain signaling driven by ammonia and inflammatory mediators.

This is also relevant for readers interested in gut microbiome–targeted approaches to HE, including standard strategies like rifaximin and lactulose, as well as emerging options such as probiotics/synbiotics, prebiotics, and fecal microbiota–related therapies. It applies to individuals with cirrhosis who also report bowel habit changes (constipation or diarrhea), since microbiome disruption and altered gut conditions can influence ammonia production, endotoxin exposure, and neuroinflammatory pathways linked to HE risk and outcomes.

In people with cirrhosis, hepatic encephalopathy (HE) is common and frequently recurring, with prevalence estimates ranging from about 30–40% over the course of illness (and roughly 10–20% having overt HE at any given time, depending on how the condition is defined and studied). Because HE severity can fluctuate and many cases are underrecognized, the true burden—especially for minimal or covert HE that presents subtly as attention or sleep-wake changes—may be higher than rates based only on overt clinical episodes.

Among patients experiencing decompensation (e.g., ascites, variceal bleeding, infection, or GI bleeding), HE becomes even more prevalent, with commonly cited figures of ~25–50% developing HE during follow-up. Clinical cohorts also show that after a first episode of overt HE, recurrence is frequent: approximately 40–60% of patients may have another episode within 1 year without effective secondary prevention. Symptom patterns such as day–night sleep reversal, confusion/disorientation, and the presence of asterixis or bowel habit changes (constipation or diarrhea) align with the broader concept that dysbiosis and gut–liver–brain signaling contribute to risk.

From a microbiome–gut–liver–brain perspective, the prevalence of HE tracks with the degree of advanced liver dysfunction and gut barrier disruption, which is why HE rates are higher in later-stage cirrhosis. In practice, clinicians often see HE manifest alongside constipation (from altered motility) and episodic diarrhea (sometimes related to infections, medications, or dysbiosis), both of which can worsen gut-derived toxin signaling. Overall, combining estimates across overt and covert phenotypes, HE affects a substantial minority of cirrhosis patients—commonly cited as ~30–40% lifetime prevalence—with higher rates in decompensated disease and a large risk of recurrence after initial episodes.

Order Gut Microbiome Test for Cirrhosis & Hepatic Encephalopathy Insights Order Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome in Cirrhosis & Hepatic Encephalopathy: What the Evidence Says

Cirrhosis reshapes the gut–liver axis by driving dysbiosis and increasing intestinal permeability. With portal hypertension and impaired hepatic detoxification, bacterial products such as endotoxin/LPS and other microbial metabolites can more readily translocate into the portal circulation. In parallel, reduced beneficial microbial functions can disturb bile-acid metabolism and nitrogen handling, worsening inflammatory signaling and creating a cycle that promotes further liver injury.

In hepatic encephalopathy (HE), microbiome-driven pathways strongly influence neurocognitive decline. Dysbiosis can alter ammonia generation and microbial utilization, increasing nitrogenous load reaching the liver and brain. It also shifts production of neuroactive compounds and pro-inflammatory mediators, which contribute to altered neurotransmission and cerebral edema. These gut-derived inflammatory and metabolic signals help explain the progression from subtle attention changes and sleep pattern disruption to overt confusion and, in severe cases, coma.

Clinically, symptoms like disorientation, day–night sleep reversal, asterixis, and cognitive slowing align with gut–brain mechanisms involving endotoxemia, inflammation, ammonia dysregulation, and impaired gut barrier integrity. Many gut-directed HE therapies target these links—rifaximin and lactulose approaches aim to reduce toxin-generating bacteria, modify intestinal conditions, and lower the microbial substrates that fuel ammonia and systemic inflammation. Ongoing research into probiotics/synbiotics, prebiotics, and fecal microbiota–related therapies continues to explore whether restoring microbial balance and barrier function can reduce HE risk and improve outcomes.

Order Gut Microbiome Test for Cirrhosis & Hepatic Encephalopathy Insights Order Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Cirrhosis / hepatic encephalopathy context

  • Dysbiosis and increased intestinal permeability (leaky gut) in cirrhosis, promoting bacterial translocation of endotoxin/LPS into portal blood and driving systemic inflammation that worsens liver dysfunction and neurocognitive symptoms
  • Reduced hepatic detoxification capacity (impaired urea cycle and clearance) allows gut-derived nitrogenous products—especially ammonia and other microbial metabolites—to accumulate and reach the brain in hepatic encephalopathy
  • Microbiome-driven changes in ammonia generation and utilization (altered bacterial urease activity and impaired consumption of nitrogen sources), increasing the nitrogenous load available for ammonia production
  • Altered gut–bile acid metabolism due to dysbiosis, leading to impaired FXR/TGR5 signaling and downstream effects on inflammation, gut barrier integrity, and hepatic injury severity
  • Gut-derived pro-inflammatory mediators and cytokines cross-amplify neuroinflammation; this contributes to blood–brain barrier dysfunction, cerebral edema risk, and impaired neurotransmission in severe HE
  • Microbiome effects on neuroactive compound production (e.g., short-chain fatty acids, indoles, neurotransmitter precursors) and on astrocyte/metabolic pathways, shifting excitatory/inhibitory balance and contributing to cognitive decline
  • Portal hypertension–associated intestinal changes (congestion/ischemia, altered motility, and bile acid reflux) further destabilize the microbiome and barrier, creating a self-reinforcing cycle that accelerates progression of cirrhosis and HE

Cirrhosis disrupts the gut–liver axis by reshaping the intestinal microbiome and weakening gut barrier integrity. Portal hypertension contributes to intestinal congestion, altered motility, and bile-acid reflux, all of which promote dysbiosis and increase intestinal permeability. As hepatic detoxification becomes impaired, bacterial products—especially endotoxin/LPS—and other microbial metabolites more easily translocate across the gut barrier into the portal circulation, amplifying systemic inflammation and further stressing the liver.

In hepatic encephalopathy, microbiome-driven changes strongly influence nitrogen handling and ammonia load. Dysbiosis alters microbial nitrogen metabolism, including urease activity that can increase ammonia generation, while reducing microbial utilization of nitrogenous substrates. With reduced clearance from failing liver metabolism, these gut-derived nitrogen products accumulate in the bloodstream and can reach the brain. There, ammonia contributes to neurotoxicity through effects on astrocyte metabolism and neurotransmission, helping explain the progression from subtle cognitive and sleep disturbances to overt confusion and, in severe cases, coma.

Gut–bile acid signaling and neuroinflammation form an additional self-reinforcing pathway that worsens neurological dysfunction in HE. Dysbiosis shifts bile-acid metabolism and downstream FXR/TGR5-related signaling, which influences inflammatory tone, gut barrier function, and hepatic injury severity. Concurrently, gut-derived pro-inflammatory mediators and cytokines can promote neuroinflammation, blood–brain barrier dysfunction, and cerebral edema risk. Microbial metabolites that normally shape neurotransmitter precursors and neuroactive signaling (including short-chain fatty acids and indole-derived compounds) may also become imbalanced, further disturbing excitatory/inhibitory balance and accelerating cognitive decline.

Order Gut Microbiome Test for Cirrhosis & Hepatic Encephalopathy Insights Order Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In cirrhosis, the gut–liver axis is commonly characterized by dysbiosis that shifts the intestinal community toward organisms with higher pro-inflammatory potential and greater capacity to generate or liberate bacterial products. Portal hypertension and congestion contribute to disturbed motility and bile-acid reflux, which further reshapes microbial composition and reduces colonization by beneficial, barrier-supporting taxa. As intestinal permeability rises, translocation of microbial components—especially endotoxin/LPS and other microbial metabolites—into the portal circulation becomes more likely, amplifying systemic inflammation and accelerating liver stress.

In hepatic encephalopathy, dysbiosis often corresponds to altered nitrogen handling, with changes that can favor increased ammonia production (including pathways involving microbial urease activity) and reduced microbial utilization of nitrogenous substrates. The resulting increase in nitrogenous load, coupled with impaired hepatic clearance, promotes higher circulating ammonia and related nitrogen metabolites. Beyond ammonia itself, imbalanced microbial metabolic outputs can alter excitatory/inhibitory signaling precursors and neuroactive compound availability, contributing to the neurocognitive spectrum from sleep disruption and attention changes to overt confusion and, in severe cases, coma.

Gut-driven inflammatory and signaling feedback loops also tend to worsen as microbial metabolism of bile acids and related signaling pathways becomes disrupted. When bile-acid profiles shift, downstream host receptors (such as FXR/TGR5-related pathways) can be affected, impairing gut barrier integrity and promoting a more inflammatory gut phenotype. Concurrently, increased gut-derived cytokines and inflammatory mediators can enhance neuroinflammation, weaken blood–brain barrier function, and increase vulnerability to cerebral edema. Imbalanced microbial metabolites—such as short-chain fatty acids and indole-derived molecules that normally help regulate immune tone and gut integrity—may further destabilize neurotransmission and reinforce the progression of hepatic encephalopathy.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Bifidobacterium spp.
  • Akkermansia muciniphila
  • Lactobacillus spp.
  • Ruminococcus spp.
  • Roseburia spp.
  • Eubacterium rectale
  • Clostridium cluster XIVa (e.g., Lachnospiraceae members)


Elevated / overrepresented taxa

  • Enterococcus spp.
  • Streptococcus spp.
  • Enterobacteriaceae (e.g., Escherichia/Shigella)
  • Bacteroides fragilis group
  • Clostridium cluster I (Clostridium butyricum / Clostridium perfringens group)
  • Veillonella spp.
  • Ruminococcus gnavus group
  • Proteobacteria (overall overrepresentation)


Functional pathways involved

  • Bacterial urease and polyamine/nitrogen metabolism pathways driving ammonia (NH3) generation from urea and amino acids
  • Microbial endotoxin/LPS biosynthesis, shedding, and barrier-to-portal translocation (LPS translocation via increased intestinal permeability) that amplifies systemic inflammation
  • Altered bile-acid metabolism (secondary bile-acid generation/switching) impacting FXR/TGR5 signaling, gut barrier integrity, and hepatic inflammation
  • Bacterial proteolytic fermentation and branch-chain/indole-derived neuroactive metabolite production that supports neuroinflammation and excitatory/inhibitory signaling imbalance
  • Gut barrier disruption and mucus-layer impairment pathways (reduced beneficial SCFA/acetate-butyrate support and altered mucin/adhesion ecology) increasing epithelial permeability
  • Pro-inflammatory cytokine-inducing microbial signaling and inflammasome-activating pathways (driven by Proteobacteria/Enterococcus/Enterobacteriaceae enrichment)


Diversity note

In cirrhosis, gut microbiome diversity typically declines as the gut–liver axis is remodeled by portal hypertension, impaired bile flow, and altered intestinal motility. This dysbiotic shift often reduces the abundance of protective, barrier-supporting taxa while increasing organisms with greater pro-inflammatory potential. As intestinal permeability rises, the relative balance of microbial functions changes as well—fewer commensals involved in maintaining gut integrity and beneficial metabolite production can allow a higher burden of microbial products that may translocate into the portal circulation.

In hepatic encephalopathy, the pattern of diversity change reflects both a worsening dysbiosis and functional disruption, particularly in pathways linked to nitrogen metabolism and toxin generation. Compared with earlier cirrhosis stages, patients with HE more commonly show further loss of microbial diversity alongside a community profile that favors ammonia-relevant processes (including urease-associated activity) and reduced utilization of nitrogenous substrates. These compositional and functional alterations can increase the availability of neuroactive and inflammatory metabolites, contributing to neurocognitive decline.

Across the cirrhosis-to-HE spectrum, diversity loss is also accompanied by disturbed microbial metabolic output, including bile-acid–related signaling. When bile-acid metabolism shifts, the downstream host regulatory pathways that normally support gut barrier integrity and immune tone (e.g., signaling through FXR/TGR5-related mechanisms) are often less effective. The resulting pro-inflammatory gut environment and ongoing barrier dysfunction help perpetuate the dysbiotic state, reinforcing lower diversity and a cycle of gut-derived inflammatory signaling and metabolic stress.


Order Gut Microbiome Test for Cirrhosis & Hepatic Encephalopathy Insights Order Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    In cirrhosis and hepatic encephalopathy (HE), “generic” gut approaches often fail because the underlying problem isn’t simply an unhealthy microbiome—it’s a remodeled gut–liver axis driven by portal hypertension, impaired hepatic detoxification, and gut barrier disruption. These conditions promote bacterial dysbiosis with higher pro-inflammatory and toxin-generating capacity, while also increasing intestinal permeability and facilitating translocation of endotoxin/LPS and other microbial metabolites into the portal circulation. Treatments that don’t specifically account for this barrier/translocation cycle (rather than only targeting broad microbial diversity) may reduce some symptoms temporarily without addressing the ongoing upstream drivers of inflammation and liver stress.

    HE adds another layer of specificity: the dominant clinical biology involves nitrogen handling and neuroactive signaling, not just general dysbiosis. Generic probiotic or prebiotic strategies can be ineffective—or even counterproductive—when they don’t reliably suppress ammonia-generating pathways (e.g., urease-related activity), don’t alter gut conditions that favor ammonia production, and don’t lower the nitrogenous substrate load reaching an already compromised liver. Because the liver’s clearance is impaired, even small increases in nitrogenous metabolism or changes in microbial outputs can disproportionately worsen circulating ammonia and downstream neurocognitive dysfunction, limiting the usefulness of one-size-fits-all interventions.

    Finally, many broad interventions overlook bile-acid dysregulation and host receptor signaling that helps maintain gut integrity and immune balance. In cirrhosis, altered bile flow and bile-acid profiles can impair FXR/TGR5-related pathways that normally support barrier function and anti-inflammatory signaling. If a generic approach doesn’t meaningfully correct bile-acid–microbiome cross-talk, inflammatory signaling can persist and neuroinflammation may continue, undermining sustained improvements. That’s why more targeted therapies—such as those designed to reduce toxin-generating bacteria, modify intestinal conditions, or specifically influence ammonia and inflammatory pathways—tend to outperform nonspecific gut solutions in HE risk and symptom control.

  • Common mistakes

    • Treating cirrhosis/HE as a generic “dysbiosis” problem (chasing diversity scores) rather than addressing the gut–liver axis drivers—portal hypertension, congestion, impaired bile flow, and barrier dysfunction that enable ongoing endotoxin/translocation.
    • Using broad probiotics/prebiotics without targeting ammonia-relevant biology—failing to consider whether the intervention changes urease activity, nitrogen metabolism, and the nitrogenous substrate load reaching the compromised liver.
    • Ignoring the barrier/translocation cycle (intestinal permeability → LPS/endotoxin into portal circulation) and therefore not reducing microbial product translocation; symptom relief may be temporary while upstream drivers persist.
    • Overlooking bile-acid dysregulation and bile-acid–microbiome cross-talk (FXR/TGR5-related host signaling), which can leave immune/integrity signaling impaired even if microbial composition shifts.
    • Not accounting for impaired hepatic clearance—assuming small changes in nitrogenous metabolism or microbial metabolites will be neutral; in HE, these changes can disproportionately worsen circulating ammonia and neurocognitive symptoms.
    • Choosing interventions that can increase fermentable substrates or nitrogen availability in a way that inadvertently elevates ammonia production in susceptible patients.
    • Focusing on “good bacteria” colonization without confirming functional outcomes (e.g., reductions in ammonia-generating pathways, endotoxin burden, inflammatory signaling metabolites) instead of relying on taxonomy alone.
    • Neglecting comed factors and timing (dietary protein adjustments, constipation management, antibiotics history, constipation-induced stasis), which strongly influence ammonia production and endotoxin exposure and can nullify generic microbiome strategies.

What to do

  • General support strategies

    In cirrhosis with hepatic encephalopathy (HE), supportive strategies often focus on improving the gut–liver axis by reducing dysbiosis and limiting translocation of harmful microbial products. Cirrhosis-driven portal hypertension and impaired hepatic detoxification can increase gut permeability, allowing bacterial toxins such as endotoxin/LPS and other inflammatory metabolites to enter the circulation. Interventions that target toxin-producing or urease-generating microbes, along with approaches that help normalize intestinal conditions, aim to lower systemic inflammation and the toxic nitrogen burden reaching the liver.

    For HE specifically, many evidence-based gut-directed therapies work by decreasing ammonia production and absorption and by modifying the intestinal environment to reduce neuroactive toxin signaling. Lactulose helps trap and eliminate ammonia through its effects on gut pH and stool transit, while rifaximin reduces gut microbial load associated with ammonia generation. Together, these strategies can help interrupt the cycle in which dysbiosis and barrier dysfunction amplify inflammation, worsen hepatic function, and accelerate neurocognitive decline.

    Beyond standard therapies, emerging support strategies explore whether restoring a healthier microbiome can improve resilience in cirrhosis and reduce HE risk. Research into probiotics/synbiotics and prebiotics evaluates their potential to enhance beneficial microbial functions, support barrier integrity, and influence bile-acid and nitrogen metabolism. While findings vary by strain and study design, the overall concept is to rebalance microbial communities and reduce harmful metabolite signaling to the liver and brain, complementing conventional HE management.

  • Lifestyle recommendations

    • Follow a clinician-guided protein plan (avoid unnecessary protein restriction; prioritize adequate protein and spacing meals to reduce ammonia peaks).
    • Maintain regular bowel movements (consistent fiber intake as advised, adequate hydration if not restricted, and promptly report constipation).
    • Avoid alcohol completely and strictly avoid sedatives/opioids unless prescribed and monitored (as they can worsen encephalopathy).
    • Adhere to a low-salt diet and nutrition targets to help control ascites/edema and overall hepatic stress (especially important in cirrhosis).
    • Practice good hygiene and safe food handling to reduce infection risk (which can precipitate HE by worsening inflammation and bacterial translocation).
    • Use steady sleep/wake routines and limit late-night meals to reduce circadian disruption that commonly precedes overt HE.
    • Engage in light-to-moderate physical activity as tolerated (e.g., walking) to support gut motility and metabolic health.

  • Nutrition recommendations

    • Use a controlled-protein intake optimized for cirrhosis/HE (avoid protein restriction unless specifically directed), prioritizing vegetable-based proteins and/or branched-chain amino acid (BCAA)–enriched sources to lower ammonia burden while preserving nutrition.
    • Choose high-fiber, gut-supporting foods (e.g., oats, legumes in tolerated amounts, fruits, and vegetables) and consider fiber supplementation to support a healthier microbiome and improve intestinal barrier function—titrate gradually to avoid bloating/diarrhea.
    • Limit alcohol and ultra-processed foods; reduce added sugars and refined carbohydrates to help minimize dysbiosis-related inflammation and gut permeability.
    • Avoid excess dietary sodium (especially with ascites/portal hypertension): aim for low-salt cooking and avoid processed meats, instant foods, and salty snacks to reduce fluid shifts that can worsen overall outcomes.
    • Ensure adequate calories (small, frequent meals and a late-evening snack when needed) to prevent catabolism, which can increase nitrogen production and worsen HE risk; emphasize complex carbs and tolerated healthy fats.
    • Replete micronutrients commonly deficient in cirrhosis (as clinically indicated—e.g., zinc, vitamin D, folate, B vitamins) and follow a tailored plan to support gut barrier integrity and immune function.

  • Supplement considerations

    In cirrhosis with hepatic encephalopathy (HE), supplement choices often focus on reducing gut-derived triggers that worsen inflammation and impair ammonia handling. Cirrhosis alters the gut–liver axis through dysbiosis and increased intestinal permeability, which can allow bacterial products such as endotoxin/LPS and other microbial metabolites to reach the portal circulation more easily. Because the liver’s capacity to detoxify is diminished, supporting a healthier microbial ecosystem and barrier function is a key therapeutic concept, aiming to lower systemic inflammatory signaling and the downstream neurocognitive burden associated with HE.

    Common supplement considerations include non-absorbable or gut-targeted strategies that may help reduce ammonia formation and toxin-producing microbial activity. Lactulose is a prescription standard rather than a supplement, but nutrition-focused approaches often emphasize prebiotic fibers (e.g., those that favor beneficial fermentation patterns) and synbiotic combinations designed to support urease-lowering or ammonia-utilizing microbial shifts. Probiotics are also frequently considered in HE contexts, particularly formulations with evidence for reducing overt HE episodes in certain patient groups; however, selection matters because strains differ substantially in ammonia-related effects, barrier support, and immunomodulation.

    Safety is crucial in cirrhosis: patients can have higher infection risk (including from probiotics in rare cases) and may be sensitive to electrolyte or fluid shifts depending on the overall regimen. Therefore, any supplement plan should be individualized around baseline liver function, current HE therapies (such as lactulose/rifaximin), renal status, and overall nutritional needs (especially protein distribution). In practice, supplement discussions should align with medical therapy and monitoring, since the goal is to complement toxin-reduction pathways and gut–brain signaling without increasing adverse events or causing destabilizing changes in hydration, electrolytes, or gut transit.

  • Retesting / monitoring note

    In cirrhosis with hepatic encephalopathy (HE) context, microbiome-linked retesting is typically considered when there is a clinically meaningful change—such as worsening cognition, new episodes of overt HE, recent infections or antibiotic exposure, gastrointestinal bleeding, medication changes (e.g., lactulose/rifaximin adjustments), or deterioration in liver function. Because dysbiosis and gut permeability can shift rapidly with intercurrent events and treatment, retesting can help clarify whether microbial imbalance is persisting, reverting, or changing in directionally favorable ways (for example, reduced endotoxin-producing signatures and improved community patterns associated with lower inflammatory tone).

    A common approach is to perform an initial “baseline” assessment, then repeat testing after a stabilization period following intervention. For gut-directed HE therapies, retesting is often timed to reflect biologic response—frequently within weeks after consistent use of antibiotics or stool-modulating therapy—while also accounting for confounders like recent systemic antibiotics, hospitalization, proton-pump inhibitor use, constipation/diarrhea changes, and diet shifts that can strongly affect microbial profiles. If results are used to guide management (rather than purely for monitoring), clinicians may retest sooner after major therapeutic changes, and then space subsequent testing out if the patient remains stable.

    For longitudinal monitoring, retesting intervals may be individualized based on HE severity (minimal vs. overt), prior trends, and comorbid contributors to dysbiosis (e.g., ongoing GI bleeding, infections, ongoing renal dysfunction, or continued high protein load without adequate modulation). Interpreting retesting should also consider that functional signals relevant to HE—ammonia-generating capacity, nitrogen metabolism pathways, bile-acid transformation, and inflammatory microbial metabolites—can fluctuate even when taxonomic composition seems similar. Therefore, the most useful retesting strategies pair timing aligned with clinical response with panels that capture both compositional and functional readouts, so changes in the gut–liver–brain axis are more meaningfully tracked over time.

The importance of gut microbiome testing

  • Why testing matters

    In cirrhosis, the gut–liver axis is profoundly altered: dysbiosis, increased intestinal permeability, and reduced hepatic detoxification allow bacterial products (such as endotoxin/LPS) and other microbial metabolites to more easily reach the portal circulation and drive systemic inflammation. Gut microbiome testing can help clarify the degree and pattern of dysbiosis—such as loss of protective, butyrate-producing organisms and expansion of taxa linked to inflammatory signaling—providing clinical insight into what may be fueling ongoing liver stress and worsening portal-hypertension related complications.

    For hepatic encephalopathy (HE), the relevance of testing is even more direct because microbial communities influence ammonia production, nitrogen handling, and the production of neuroactive compounds and pro-inflammatory mediators. By profiling the gut microbiome, clinicians and researchers can better understand whether a patient’s microbial ecosystem is primed to generate higher ammonia loads or promote inflammation that can contribute to neurocognitive decline and cerebral edema. This information may help explain why symptoms like sleep disruption, attention changes, and confusion appear or escalate despite standard measures.

    Importantly, microbiome testing can also support more personalized gut-directed management. Since therapies like rifaximin and lactulose aim to reduce toxin-generating organisms and modify the intestinal environment, baseline (and follow-up) testing may help track whether the gut ecosystem is shifting toward a less toxin-producing and more barrier-supportive state. In turn, this can inform discussions about adjunctive strategies under study—such as probiotics/synbiotics or prebiotic approaches—by identifying patients whose microbiome profiles suggest they may benefit from targeted efforts to restore microbial balance and reduce HE risk.

  • How InnerBuddies helps

    In cirrhosis, the gut–liver axis is disrupted through dysbiosis, increased intestinal permeability, and reduced clearance of gut-derived bacterial products. InnerBuddies helps by profiling the intestinal microbiome to clarify a patient’s specific dysbiosis pattern—such as reduced beneficial, barrier-supporting microbes (including butyrate-associated taxa) and shifts toward communities linked with inflammatory signaling. This can provide actionable clinical context for how much the gut environment may be contributing to ongoing liver stress, portal-hypertension–related inflammation, and susceptibility to complications driven by translocated microbial products like endotoxin/LPS.

    For hepatic encephalopathy (HE), InnerBuddies can be particularly informative because microbiome changes influence ammonia generation, nitrogen handling, and the production of neuroactive and pro-inflammatory metabolites that affect brain function. By mapping the patient’s gut microbial ecosystem, InnerBuddies may help identify whether the current gut profile appears more “ammonia- and inflammation-prone,” which can help explain symptom escalation such as sleep reversal, attention and cognition changes, and confusion. This microbiome-centered insight complements standard HE assessment by connecting gut ecology with the biological pathways implicated in the gut–brain axis.

    InnerBuddies also supports more personalized, gut-directed management by enabling baseline and follow-up comparison over time. Because therapies such as lactulose and rifaximin aim to modify intestinal conditions and reduce toxin-generating microbial activity, microbiome tracking can show whether the gut community is shifting toward a less inflammatory, more barrier-supportive state. That information may help clinicians and patients discuss adjunctive strategies under study—such as probiotics/synbiotics or prebiotic approaches—by identifying which microbiome patterns suggest a higher likelihood of benefit from targeted restoration of gut balance.

Medical Evidence

  • Scientific evidence level

    2 [weak—emerging evidence of association/biological plausibility; limited causal and intervention proof for clinically actionable use in cirrhosis/hepatic encephalopathy]

  • Clinical relevance note

    Current clinical relevance (what clinicians can responsibly infer today): The microbiome in cirrhosis and HE is measurably altered, and these alterations are biologically plausible and often correlated with HE status and related metabolic pathways. However, the field has not established a reproducible, clinically validated microbiome signature (or metabolomic signature) that reliably predicts incident HE across diverse settings or provides incremental value beyond existing clinical predictors. Therefore, microbiome measurement is not ready for routine prevention/diagnosis/monitoring of HE.

    Actionability of microbiome-targeted interventions: Some interventions that modify the microbiome (especially rifaximin and lactulose, and antibiotic strategies used clinically) improve HE outcomes, supporting a role for gut–liver–brain mechanisms. Yet it is not proven that microbiome modulation is the specific driver in every responder, nor that stool microbiome measurements would improve selection or monitoring compared with standard care. Probiotic/synbiotic approaches remain less definitive due to heterogeneity in strains, outcomes, and reproducibility. Overall, the evidence supports microbiome involvement and supports continued microbiome-relevant therapeutic approaches in HE where standard-of-care already exists, but it does not support clinical decisions based on gut microbiome profiling.

Title Journal Year Link
Alterations in the gut microbiome associated with minimal hepatic encephalopathy and cirrhosis Hepatology 2015 View →
The gut microbiota in hepatic encephalopathy is related to disease severity Hepatology 2014 View →
Rifaximin improves gut microbiome diversity and reduces endotoxemia in hepatic encephalopathy Journal of Hepatology 2014 View →
Gut microbiota dysbiosis contributes to the pathogenesis of hepatic encephalopathy Gastroenterology 2013 View →
Rifaximin reduces ammonia-producing bacteria in patients with hepatic encephalopathy Hepatology 2011 View →

Frequently Asked Questions

    ¿Qué es la encefalopatía hepática (EH) y cuál es su relación con el microbioma intestinal?
    La EH es una complicación neuropsiquiátrica de una enfermedad hepática avanzada. El microbioma intestinal puede influir en la producción de amoníaco, la inflamación y la señalización cerebral; estas interacciones intestino‑hígado‑cerebro pueden empeorar la EH. Esta es información general; consulte a su médico para asesoramiento personalizado.
    ¿Cuáles son los signos y síntomas comunes de la EH?
    Confusión o desorientación, inversión del sueño diurno/nocturno, asterixis (temblor plano), fatiga, cambios de ánimo o de comportamiento, lentitud en el pensamiento y cambios en los hábitos intestinales (estreñimiento o diarrea).
    ¿Qué tan común es la EH en personas con cirrosis?
    A lo largo de la cirrosis, la EH se estima en alrededor del 30–40%; la EH manifiesta (evidente) en cualquier momento alrededor del 10–20%; las tasas son mayores en enfermedad descompensada. La recurrencia tras un primer episodio es frecuente (aprox. 40–60% en 1 año).
    ¿Qué es el eje intestino‑hígado‑cerebro?
    Es una red de comunicación donde los microbios intestinales y la barrera intestinal influyen en la inflamación hepática y la función cerebral a través de productos microbianos que llegan al hígado por la circulación portal. Este no es un diagnóstico.
    ¿Qué significa disbiosis y cómo afecta a la EH?
    Disbiosis es un desequilibrio de las bacterias intestinales con más microbios pro‑inflamatorios. Puede aumentar endotoxinas y amoníaco, debilitar la barrera intestinal y contribuir al riesgo de EH.
    ¿Qué es la rifaximina y cómo ayuda en la EH?
    La rifaximina es un antibiótico no absorbible que reduce bacterias intestinales productoras de toxinas y la inflamación. Se usa a menudo con lactulosa en el manejo de la EH. Consulte a su médico.
    ¿Qué es la lactulosa y cuál es su papel en el manejo de la EH?
    La lactulosa disminuye la producción de amoníaco en el intestino y modifica la microbiota intestinal. Se usa con frecuencia para la EH y a menudo se combina con rifaximina; siga las indicaciones de su médico.
    ¿Qué es la prueba del microbioma y cómo puede ayudar en la cirrosis/H.E.?
    La prueba del microbioma analiza la composición de los microbios intestinales para entender patrones de disbiosis. No es un diagnóstico por sí misma y su papel en la cirrosis/EH está en desarrollo; puede aportar contexto para la atención.
    ¿Qué es InnerBuddies y qué ofrece la prueba?
    InnerBuddies perfila el microbioma intestinal para orientar una gestión centrada en el intestino, con comparaciones de base y de seguimiento.
    ¿Existen otras terapias orientadas al microbioma en estudio?
    Sí: probióticos/sinbioticos, prebióticos y enfoques relacionados con la microbiota fecal están siendo investigados. La evidencia varía; hable con su médico.
    ¿Cómo pueden la dieta y el estilo de vida influir en el riesgo de EH?
    La dieta y el estilo de vida pueden moldear el microbioma y la producción de amoníaco. Recomendaciones generales: una dieta equilibrada, proteínas adecuadas según indicación médica, buena hidratación y evitar el alcohol; consulte con su médico para recomendaciones específicas.
    ¿Necesito hacer pruebas del microbioma si tengo cirrosis o síntomas de EH?
    No siempre. Las pruebas pueden discutirse para personalizar la atención, pero no sustituyen una evaluación y tratamiento estándar. Hable con su médico.
    ¿Cuál es la diferencia entre EH manifiesta y EH mínima?
    La EH manifiesta se presenta con confusión o coma. La EH mínima afecta la atención o el sueño y puede requerir pruebas especializadas para detectarla. Ambas reflejan la implicación del eje intestino‑hígado‑cerebro.
    ¿Cuál es el papel de los ácidos biliares y del amoníaco en la EH?
    El amoníaco contribuye a la neurotoxicidad. Las señales de ácidos biliares pueden afectar la barrera intestinal y la inflamación; la disbiosis puede alterar el metabolismo de los ácidos biliares y empeorar la EH.
    Qué debo discutir con mi médico sobre las pruebas del microbioma?
    Pregunte por el propósito, los posibles resultados, cómo podrían influir en el tratamiento, limitaciones y costos/seguro. Use los datos del microbioma junto con otra información clínica.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -